FTC Issues Final Authorized Generic Report


On August 31, the Federal Trade Commission (FTC) issued its final report on the effect of authorized generic drugs (AGs) on competition in the prescription drug market.1 The August 2011 final report followed up on the FTC's 2009 interim report, which focused on the effects of authorized generics during the initial 180-day period of competition by a generic drug.

The FTC undertook these analyses at the request of Senators Chuck Grassley, Patrick Leahy, and John Rockefeller, as well as Representative Henry Waxman, who asked the commission to examine the competitive impact of authorized generics in the pharmaceutical industry over both the short term and the long term. FTC Chairman Jon Leibowitz (then a commissioner) also was an early proponent of the FTC examining the competitive effects of AGs.2

Please see full article below for more information.

LOADING PDF: If there are any problems, click here to download the file.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Wilson Sonsini Goodrich & Rosati | Attorney Advertising

Written by:


Wilson Sonsini Goodrich & Rosati on:

JD Supra Readers' Choice 2016 Awards
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.

Already signed up? Log in here

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.